The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
SAN DIEGO, June 15, 2026 /PRNewswire/ -- Soleno Therapeutics, a Neurocrine Biosciences (Nasdaq: NBIX) company, today announced late-breaking data at ENDO 2026 showing that resuming treatment with ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Shares of Soleno Therapeutics (NASDAQ:SLNO) fell on Wednesday after a federal database indicated that a 17-year-old male treated with the company’s recently launched rare disease therapy Vykat XR had ...
Hosted on MSN
Soleno Therapeutics, Inc. (SLNO) Targets EMA Approval as U.S. Launch of VYKAT XR Expands
In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. Soleno Therapeutics, Inc. is one of them. Soleno Therapeutics, Inc. (NASDAQ:SLNO) tops our list for ...
Fourth quarter net revenue was $91.7 million, with full year net revenue at $190.4 million, both explicitly stated by MacKaness. Cash from operating activities in Q4 was $48.7 million, and the year ...
Soleno Therapeutics plans to offer $200 million in common stock to fund commercialization of VYKAT™ XR and other activities. Soleno Therapeutics, Inc. announced its plan to conduct a public offering ...
Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the best performing mid cap stocks so far in 2025. On July 10, Soleno Therapeutics announced that the sales of its new Prader-Willi disease drug, ...
REDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results